Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lee, Mei Yueh ^a,b,c   Tsai, Kun Bow ^c   Hsu, Jong Hau ^a,b   Shin, Shyi Jang ^b   Wu, Jiunn Ren ^a,b   Yeh, Jwu Lai ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GUANYLATE CYCLASE; LIRAGLUTIDE; MONOCROTALINE; NOS3 PROTEIN, RAT; PLATELET DERIVED GROWTH FACTOR B; RHO KINASE;

ANIMAL; CELL CYCLE; CELL MOTION; CHEMISTRY; FLOW CYTOMETRY; HEMODYNAMICS; MALE; METABOLISM; PULMONARY HYPERTENSION; RAT; WISTAR RAT;

ANIMALS; CELL CYCLE; CELL MOVEMENT; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENDOTHELIN-1; FLOW CYTOMETRY; GUANYLATE CYCLASE; HEMODYNAMICS; HYPERTENSION, PULMONARY; LIRAGLUTIDE; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES;

EID: 84984865400     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31788     Document Type: Article

References (31)

1. Movahed, M. R., Hashemzadeh, M. & Jamal, M. M. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest 128, 3568-3571 (2005).
2. Schachinger, V., Britten, M. B. & Zeiher, A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906 (2000).
3. Amabile, N. et al. Circulating endothelial microparticles levels predict hemodynamic severity of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 177, 1268-1275 (2008).
4. Zanetti, M. et al. Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat. Atherosclerosis 181, 69-73 (2005).
5. Dupuis, J. Endothelin: setting the scene in PAH. Eur. Respir. Rev. 16, 3-7 (2007).
6. McLaughlin, V. V. & McGoon, M. D. Pulmonary arterial hypertension. Circulation 114, 1417-1431 (2006).
7. Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E. & Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84, 9265-9269 (1987).
8. Dupont, L. L., Glynos, C., Bracke, K. R., Brouckaert, P. & Brusselle, G. G. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases. Pulm. Pharmacol. Ther. 29, 1-6 (2014).
9. Casteel, D. E. et al. A crystal structure of the cyclic GMP-dependent protein kinase I{beta} dimerization/docking domain reveals molecular details of isoform-specific anchoring. J. Biol. Chem. 285, 32684-32688 (2010).
10. Leung, T., Chen, X. Q., Manser, E. & Lim, L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell Biol. 16, 5313-5327 (1996).
11. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006).
12. Ussher, J. R. & Drucker, D. J. Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187-215 (2012).
13. Barst, R. J. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 40S-47S (2004).
14. Kay, J. M., Keane, P. M., Suyama, K. L. & Gauthier, D. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax 37, 88-96 (1982).
15. Hoorn, C. M. & Roth, R. A. Monocrotaline pyrrole-induced changes in angiotensin-converting enzyme activity of cultured pulmonary artery endothelial cells. Br. J. Pharmacol. 110, 597-602 (1993).
16. Ferreira, A. J. et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179, 1048-1054 (2009).
17. Prié, S., Leung, T. K., Cernacek, P., Ryan, J. W. & Dupuis, J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J. Pharmacol. Exp. Ther. 282, 1312-1318 (1997).
18. Brunner, F. Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rat. Cardiovasc. Res. 44, 197-206 (1999).
19. Ramzy, D. et al. Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation 114 (1 Suppl), 1319-1326 (2006).
20. Mills, T. M. New biochemical pathway may control erection. Scientific World Journal 1, 184-185 (2001).
21. Guignabert, C. et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111, 2812-2819 (2005).
22. Asmar, M. & Holst, J. J. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr. Opin. Endocrinol. Diabetes Obes. 17, 57-62 (2010).
23. Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S. & O'Hare, J. P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3, pii:e001986 (2013).
24. Kanno, S., Wu, Y. J., Lee, P. C., Billiar, T. R. & Ho, C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104, 945-950 (2001).
25. Chung, H. H. et al. The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase. Br. J. Pharmacol. 160, 971-986 (2010).
26. Evgenov, O. V., Ichinose, F., Evgenov, N. V., Gnoth, M. J. & Falkowski, G. E. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110, 2253-2259 (2004).
27. Murray, F., MacLean, M. R. & Pyne, N. J. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br. J. Pharmacol. 137, 1187-1194 (2002).
28. 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc. Drugs Ther. 29, 243-255 (2015).
29. Romaní-Pérez, M. et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology 156, 3559-3569 (2015).
30. Wu, J. R. et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol. Res. 59, 48-56 (2009).
31. Wu, B. N. et al. Inhibition of proinflammatory tumor necrosis factor-α-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-3) in rat trachea: the involvement of soluble guanylate cyclase and protein kinase G. Mol. Pharmacol. 70, 977-985 (2006).